The multifaceted circulating endothelial cell in cancer: Towards marker and target identification

Francesco Bertolini; Yuval Shaked; Patrizia Mancuso; Robert S. Kerbel

doi:10.1038/nrc1971

The multifaceted circulating endothelial cell in cancer: Towards marker and target identification

Francesco Bertolini, Yuval Shaked, Patrizia Mancuso, Robert S. Kerbel

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

Increases in the number of circulating endothelial cells (CECs) and progenitors (CEPs) have been reported in various pathological conditions including cancer. Preclinical studies have shown that CEC and CEP kinetics correlate well with several standard laboratory angiogenesis assays, which cannot be used in humans. At the clinical level, evidence is emerging that CEC kinetics and viability might correlate with clinical outcomes in cancer patients who undergo anti-angiogenic treatment. Therefore, CEC and CEP measurement has potential as a surrogate marker for monitoring anti-angiogenic treatment and drug activity, and could help to determine the optimal biological dose of anti-angiogenic drugs, which are being used with increasing frequency in medical oncology.

Original language	English
Pages (from-to)	835-845
Number of pages	11
Journal	Nature Reviews Cancer
Volume	6
Issue number	11
DOIs	https://doi.org/10.1038/nrc1971
Publication status	Published - Nov 12 2006

ASJC Scopus subject areas

Cancer Research

Access to Document

10.1038/nrc1971

Fingerprint Dive into the research topics of 'The multifaceted circulating endothelial cell in cancer: Towards marker and target identification'. Together they form a unique fingerprint.

Cite this

@article{27c3004ff37e4310b1106b3fdd8ab659,

title = "The multifaceted circulating endothelial cell in cancer: Towards marker and target identification",

abstract = "Increases in the number of circulating endothelial cells (CECs) and progenitors (CEPs) have been reported in various pathological conditions including cancer. Preclinical studies have shown that CEC and CEP kinetics correlate well with several standard laboratory angiogenesis assays, which cannot be used in humans. At the clinical level, evidence is emerging that CEC kinetics and viability might correlate with clinical outcomes in cancer patients who undergo anti-angiogenic treatment. Therefore, CEC and CEP measurement has potential as a surrogate marker for monitoring anti-angiogenic treatment and drug activity, and could help to determine the optimal biological dose of anti-angiogenic drugs, which are being used with increasing frequency in medical oncology.",

author = "Francesco Bertolini and Yuval Shaked and Patrizia Mancuso and Kerbel, {Robert S.}",

year = "2006",

month = nov,

day = "12",

doi = "10.1038/nrc1971",

language = "English",

volume = "6",

pages = "835--845",

journal = "Nature Reviews Cancer",

issn = "1474-175X",

publisher = "Nature Publishing Group",

number = "11",

}

TY - JOUR

T1 - The multifaceted circulating endothelial cell in cancer

T2 - Towards marker and target identification

AU - Bertolini, Francesco

AU - Shaked, Yuval

AU - Mancuso, Patrizia

AU - Kerbel, Robert S.

PY - 2006/11/12

Y1 - 2006/11/12

N2 - Increases in the number of circulating endothelial cells (CECs) and progenitors (CEPs) have been reported in various pathological conditions including cancer. Preclinical studies have shown that CEC and CEP kinetics correlate well with several standard laboratory angiogenesis assays, which cannot be used in humans. At the clinical level, evidence is emerging that CEC kinetics and viability might correlate with clinical outcomes in cancer patients who undergo anti-angiogenic treatment. Therefore, CEC and CEP measurement has potential as a surrogate marker for monitoring anti-angiogenic treatment and drug activity, and could help to determine the optimal biological dose of anti-angiogenic drugs, which are being used with increasing frequency in medical oncology.

AB - Increases in the number of circulating endothelial cells (CECs) and progenitors (CEPs) have been reported in various pathological conditions including cancer. Preclinical studies have shown that CEC and CEP kinetics correlate well with several standard laboratory angiogenesis assays, which cannot be used in humans. At the clinical level, evidence is emerging that CEC kinetics and viability might correlate with clinical outcomes in cancer patients who undergo anti-angiogenic treatment. Therefore, CEC and CEP measurement has potential as a surrogate marker for monitoring anti-angiogenic treatment and drug activity, and could help to determine the optimal biological dose of anti-angiogenic drugs, which are being used with increasing frequency in medical oncology.

UR - http://www.scopus.com/inward/record.url?scp=33750286135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750286135&partnerID=8YFLogxK

U2 - 10.1038/nrc1971

DO - 10.1038/nrc1971

M3 - Article

C2 - 17036040

AN - SCOPUS:33750286135

VL - 6

SP - 835

EP - 845

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

SN - 1474-175X

IS - 11

ER -